Moderna, Inc., commonly referred to as Moderna, is a pioneering biotechnology company headquartered in the United States. Founded in 2010, Moderna has rapidly established itself as a leader in the mRNA technology sector, focusing on the development of transformative medicines and vaccines. The company gained global recognition for its COVID-19 vaccine, which showcased the potential of mRNA technology in combating infectious diseases. With major operational regions across North America and Europe, Moderna's core products include vaccines and therapeutics targeting infectious diseases, autoimmune disorders, and cancer. The unique aspect of Moderna's approach lies in its innovative use of messenger RNA to instruct cells to produce proteins that can prevent or treat diseases. As a key player in the biotechnology industry, Moderna continues to push the boundaries of science, achieving significant milestones and contributing to public health advancements worldwide.
How does Moderna's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Moderna's score of 63 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2022, Moderna, Inc. reported total carbon emissions of approximately 115,630,000 kg CO2e across all scopes. This includes Scope 1 emissions of about 11,563,000 kg CO2e, primarily from stationary combustion (10,007,000 kg CO2e) and fugitive emissions (1,407,000 kg CO2e). Scope 2 emissions were reported at approximately 1,197,000 kg CO2e (market-based), while Scope 3 emissions were significantly higher, totalling around 86,041,000 kg CO2e, with the largest contributions from purchased goods and services (1,096,111,000 kg CO2e) and upstream transportation and distribution (44,243,000 kg CO2e). Moderna has set ambitious climate commitments, aiming for net-zero carbon emissions in Scopes 1 and 2 by 2030, with a target to reduce absolute Scope 1 and 2 GHG emissions by 90% from a 2021 baseline. Additionally, the company plans to achieve a 90% reduction in absolute Scope 3 emissions by 2045. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect a commitment to sustainability within the pharmaceutical sector. Overall, Moderna's long-term goal is to reach net-zero greenhouse gas emissions across its entire value chain by 2045, demonstrating a proactive approach to addressing climate change and reducing its environmental impact.
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 9,142,000 | 00,000,000 |
| Scope 2 | 928,000 | 0,000,000 |
| Scope 3 | 489,508,000 | 0,000,000,000 |
Moderna's Scope 3 emissions, which increased by 154% last year and increased by approximately 154% since 2021, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 88% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Moderna has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


Common questions about Moderna's sustainability data and climate commitments